Physician profile
David M Bell
NPI 1518060938
$3,585.70
in general payments reported to CMS, 2019-2025
28 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $224 · 2021: $235 · 2022: $492 · 2023: $797 · 2024: $725 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,229.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $796.11 | 2019-2025 | |
| Kestra Medical Technology Services, INC. | $326.42 | 2023-2025 | Assure Wcd |
| Pfizer INC. | $258.17 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $257.37 | 2023-2024 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $234.45 | 2019-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $184.72 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $142.32 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $135.58 | 2019-2025 | Eliquis |
| Impulse Dynamics (USA) INC. | $130.95 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.45 | 2021-2024 | Jardiance |
| Amgen INC. | $116.54 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $113.97 | 2022-2025 | |
| Atricure, INC. | $109.80 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.39 | 2019-2022 | |
| Abbott Laboratories | $93.01 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $88.55 | 2020-2023 | |
| Boston Scientific Corporation | $81.95 | 2019-2023 | Watchman Flx |
| Baxter Healthcare | $63.01 | 2022-2024 | Perclot |
| Astrazeneca Pharmaceuticals LP | $42.89 | 2019-2025 | Wainua |
| Kiniksa Pharmaceuticals International, Plc | $39.98 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $37.72 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $21.20 | 2019 | |
| Chiesi USA, INC. | $17.92 | 2020 | |
| Lundbeck LLC | $16.47 | 2019 | |
| Abiomed | $15.77 | 2025 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Preventice Services, LLC | $13.55 | 2021 | |
| Gilead Sciences, INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.